Feb 17 (Reuters) - Laboratory services provider Labcorp forecast annual profit above Wall Street estimates on Tuesday, ...

Labcorp (NYSE:LH) executives said the company delivered what CEO Adam Schechter called a “very strong year” in 2025, citing ...

Labcorp Holdings (NYSE:LH) launched the first FDA cleared blood test to aid in the initial assessment of Alzheimer’s disease, the Elecsys pTau-181 test, with nationwide availability. The company also ...

Healthcare diagnostics company Labcorp Holdings (NYSE:LH) in Q4 CY2025, but sales rose 5.6% year on year to $3.52 billion. On ...

Guidance for 2026 is for 5.4% midpoint revenue growth and 9% adjusted EPS growth, compared to 2025's 7% revenue and 13% EPS growth. Margin expansion continues, but with slightly moderated growth rates ...

Labcorp Holdings Inc. (NYSE:LH) delivered fourth-quarter adjusted earnings above expectations on Tuesday, though revenue came ...

Labcorp posted higher fourth-quarter profit boosted by growth in its diagnostic laboratories business. The company reported net income of $164.7 million, or $1.98 a share, up from $143.4 million, or ...

Labcorp (LH) stock dips as the company posts mixed Q4 2025 financials, falling short of Street forecasts for revenue while exceeding on earnings. Read more here.

Labcorp is a global life sciences company headquartered in Burlington, North Carolina. Labcorp provides at-home test kits as well as in-person testing at their laboratory facilities, which are located ...

Labcorp is now offering Roche Diagnostics' recently FDA-cleared Alzheimer’s disease blood test to help primary care doctors ...

Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the nationwide availability of the Elecsys® pTau-181 test, the first and only blood test ...

LH heads into its Q4 earnings report with rising revenue and EPS expectations, driven by Diagnostics momentum, acquisitions ...